Information

Related Research Units

Endocrinology Research
Biddinger Laboratory Research

Publications

  1. Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis. bioRxiv. 2024 Aug 27. View Abstract
  2. Gut Microbiota-Derived Trimethylamine N-Oxide Contributes to Abdominal Aortic Aneurysm Through Inflammatory and Apoptotic Mechanisms. Circulation. 2023 04 04; 147(14):1079-1096. View Abstract
  3. Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1. Science. 2022 04 15; 376(6590):eabf8271. View Abstract
  4. Evaluating human genetic support for hypothesized metabolic disease genes. Cell Metab. 2022 05 03; 34(5):661-666. View Abstract
  5. Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acids. Circulation. 2022 03 29; 145(13):969-982. View Abstract
  6. Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent. Trends Pharmacol Sci. 2021 03; 42(3):183-190. View Abstract
  7. Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes. Pediatr Diabetes. 2020 11; 21(7):1126-1131. View Abstract
  8. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol synthesis markers in a young adult population. J Clin Lipidol. 2019 Nov - Dec; 13(6):940-946. View Abstract
  9. Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction. Cell Metab. 2019 12 03; 30(6):1141-1151.e5. View Abstract
  10. Acute suppression of insulin resistance-associated hepatic miR-29 in vivo improves glycemic control in adult mice. Physiol Genomics. 2019 08 01; 51(8):379-389. View Abstract
  11. microRNA-146a-5p association with the cardiometabolic disease risk factor TMAO. Physiol Genomics. 2019 02 01; 51(2):59-71. View Abstract
  12. The beta secretase BACE1 regulates the expression of insulin receptor in the liver. Nat Commun. 2018 04 03; 9(1):1306. View Abstract
  13. FoxO1 Is Required for Most of the Metabolic and Hormonal Perturbations Produced by Hepatic Insulin Receptor Deletion in Male Mice. Endocrinology. 2018 03 01; 159(3):1253-1263. View Abstract
  14. Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2. Am J Physiol Endocrinol Metab. 2018 10 01; 315(4):E613-E621. View Abstract
  15. Fructose and glucose can regulate mammalian target of rapamycin complex 1 and lipogenic gene expression via distinct pathways. J Biol Chem. 2018 02 09; 293(6):2006-2014. View Abstract
  16. YAP suppresses gluconeogenic gene expression through PGC1a. Hepatology. 2017 12; 66(6):2029-2041. View Abstract
  17. PCSK9 Is Increased in Youth With Type 1 Diabetes. Diabetes Care. 2017 07; 40(7):e85-e87. View Abstract
  18. Hepatocyte ABCA1 Deletion Impairs Liver Insulin Signaling and Lipogenesis. Cell Rep. 2017 06 06; 19(10):2116-2129. View Abstract
  19. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017 Dec; 18(8):755-760. View Abstract
  20. Calorically restricted diets decrease PCSK9 in overweight adolescents. Nutr Metab Cardiovasc Dis. 2017 Apr; 27(4):342-349. View Abstract
  21. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 05; 134(1):61-72. View Abstract
  22. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2016 04; 101(4):1790-7. View Abstract
  23. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients. Endocrinology. 2016 Apr; 157(4):1421-9. View Abstract
  24. Insulin Dissociates the Effects of Liver X Receptor on Lipogenesis, Endoplasmic Reticulum Stress, and Inflammation. J Biol Chem. 2016 Jan 15; 291(3):1115-22. View Abstract
  25. Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9. Arterioscler Thromb Vasc Biol. 2015 Jul; 35(7):1589-96. View Abstract
  26. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015 Apr 07; 6:6498. View Abstract
  27. PKB/Akt phosphorylation of ERR? contributes to insulin-mediated inhibition of hepatic gluconeogenesis. Diabetologia. 2014 Dec; 57(12):2576-85. View Abstract
  28. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes. 2014 Sep; 63(9):3141-8. View Abstract
  29. Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins. J Lipid Res. 2014 Apr; 55(4):659-67. View Abstract
  30. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23; 505(7484):559-63. View Abstract
  31. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013 Aug; 24(8):391-7. View Abstract
  32. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012 Jun 06; 15(6):873-84. View Abstract
  33. PKCd regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans. J Clin Invest. 2011 Jun; 121(6):2504-17. View Abstract
  34. Regulation of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat Med. 2011 Mar; 17(3):356-65. View Abstract
  35. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011 Mar; 31(3):513-9. View Abstract
  36. Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab. 2010 Dec 01; 12(6):567-79. View Abstract
  37. You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice. Gut. 2010 Dec; 59(12):1625-34. View Abstract
  38. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010 Mar 04; 464(7285):121-5. View Abstract
  39. Dissecting the role of insulin resistance in the metabolic syndrome. Curr Opin Lipidol. 2009 Jun; 20(3):206-10. View Abstract
  40. Insulin Resistance in Obesity (in press). Metabolic Basis of Obesity. 2009. View Abstract
  41. Chipping away at gallstones. Nat Med. 2008 Jul; 14(7):715-6. View Abstract
  42. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008 Jul; 14(7):778-82. View Abstract
  43. Regulation of energy substrate utilization and hepatic insulin sensitivity by phosphatidylcholine transfer protein/StarD2. FASEB J. 2008 Jul; 22(7):2579-90. View Abstract
  44. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008 Feb; 7(2):95-6. View Abstract
  45. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008 Feb; 7(2):125-34. View Abstract
  46. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J Biol Chem. 2007 Aug 10; 282(32):23672-8. View Abstract
  47. Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes. 2006 Jul; 55(7):2032-41. View Abstract
  48. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006; 68:123-58. View Abstract
  49. The insulin-like growth factor axis: a potential link between glycemic index and cancer. Am J Clin Nutr. 2005 Aug; 82(2):277-8. View Abstract
  50. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes. 2005 May; 54(5):1314-23. View Abstract
  51. Characterization of phosphotyrosine containing proteins at the cholinergic synapse. FEBS Lett. 1999; 446(1):95-102. View Abstract
  52. Characterization of the tyrosine phosphorylation and distribution of dystrobrevin isoforms. FEBS Lett. 1998; 432(3):133-40. View Abstract
  53. Rapsyn clusters and activates the synapse-specific receptor tyrosine kinase MuSK. Neuron. 1996; 16(5):953-62. View Abstract

Contact Sudha Biddinger

Print Profile